Amicus Therapeutics, Inc. is named one of the best biotech stocks under $20 to buy now. Jefferies downgraded FOLD to Buy from Hold and lowered the price target to $14.50 amid takeover interest. BioMarin announced acquiring FOLD for $4.8 billion, adding therapies for Fabry and Pompe diseases generating $599 million in revenue.

Focused on rare and orphan diseases, Amicus Therapeutics, Inc. develops innovative treatments. Despite potential as an investment, other AI stocks may offer greater upside potential and less downside risk. For an undervalued AI stock benefiting from Trump-era tariffs, see the best short-term AI stock report.

Read more at Yahoo Finance: Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments